How much methionine does MOTS-c contain?

Two residues of sixteen — 12.5%, against roughly 2.3% across proteins generally, so about five-fold enriched.

What does that mean in practice?

Two oxidation-prone sites rather than one, producing diagnostic +16 and +32 Da satellites alongside the 2,174.6 Da parent mass.

MOTS-c (Mitochondrial Peptide)

Two Methionines in Sixteen Residues

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

MOTS-c is MRWQEMGYIFYPRKLR: methionine at positions 1 and 6, two residues in sixteen. At 12.5% methionine against roughly 2.3% across proteins generally, it is around five times enriched — consistent with its mitochondrial origin.

Key facts

Sequence: H-MRWQEMGYIFYPRKLR-OH
Length: 16 residues
Methionines: Two — positions 1 and 6
Methionine fraction: 12.5%
Typical across proteins: About 2.3%
Formula: C101H152N28O22S2
Cysteines: None

The arithmetic

Two methionines in a sixteen-residue peptide is one residue in eight. Methionine is among the less common amino acids, appearing at roughly 2.3% across proteins generally. Twelve and a half per cent is therefore around a five-fold enrichment, which is large enough to be worth explaining rather than dismissing as chance in a short sequence.

The formula corroborates it

C101H152N28O22S2. Two sulfur atoms, and no cysteine in the sequence — so both sulfurs are methionine thioethers. The molecular formula and the stated sequence agree with each other, which is a basic internal consistency check worth performing on any certificate and one that several compounds audited on this site failed.

Research material referenced

MOTS-C 10mg — third-party HPLC tested

View — £24.99

Why the enrichment is not surprising

MOTS-c is encoded within mitochondrial DNA, and the vertebrate mitochondrial genetic code reassigns AUA from isoleucine to methionine. Bender and colleagues argued in PNAS in 2008 that this reassignment exists precisely because it raises methionine content for antioxidant purposes. A methionine-rich peptide from that genome is the predicted result, not a coincidence.

What it means for handling

Two oxidation-prone residues rather than one. Each oxidises to the sulfoxide at +16 Da, so a degraded preparation can show +16 and +32 satellites alongside the parent mass at 2,174.6 Da. Two sites means the probability that at least one has oxidised rises faster with time and exposure than for a single-methionine peptide.

What it means analytically

The satellites are diagnostic. A +16 Da species is not an unidentified impurity — it is the parent compound with one methionine oxidised, and its presence quantifies how much oxidation has occurred. That makes MOTS-c unusually easy to assess for this particular form of degradation, which is a small compensation for being unusually prone to it.

And what it does not mean

That oxidised material is equivalent to intact material, or that a preparation showing satellites is acceptable. Oxidation changes the molecule, and a certificate should be read for whether the parent mass dominates. Material supplied here is for laboratory research only and no claim is made about any effect in any person.

Quick reference

	MOTS-c	Typical protein
Methionine fraction	12.5% (2 of 16)	~2.3%
Cysteine	None	~1.4%
Sulfur atoms	2, both methionine	Mixed Met and Cys

Extended research context

The MOTS-c (Mitochondrial Peptide) deep dive

Deep dive: why a peptide encoded in mitochondrial DNA is unusual

The human mitochondrial genome is 16,569 base pairs encoding 37 genes, and was considered fully characterised by the 1980s: thirteen respiratory-chain proteins, twenty-two transfer RNAs, two ribosomal RNAs. MOTS-c is encoded by a short open reading frame nested inside the 12S rRNA gene — sequence already annotated as doing something else, which is exactly why it went unnoticed. Humanin, found in 2001 inside the 16S rRNA gene, established that the genome held more than its annotation suggested; MOTS-c was found in 2015 by looking deliberately. The implication is that the mitochondrion encodes and releases signalling molecules of its own, rather than only executing instructions sent from the nucleus.

Deep dive: AMPK activation without touching AMPK

AMPK is normally activated when AMP and ADP bind its gamma subunit, making it a direct sensor of the AMP-to-ATP ratio. MOTS-c does not raise that ratio and does not bind the kinase. It inhibits the folate cycle, the one-carbon pathway feeding de novo purine biosynthesis, and the intermediate AICAR accumulates as a result. AICAR is an AMP mimetic — phosphorylated to ZMP, it binds the same regulatory site AMP occupies. So the peptide reaches a cytosolic energy sensor through one-carbon metabolism and a diffusible small molecule, which is a materially different architecture from a receptor-ligand interaction, and different again from metformin's inhibition of complex I.

Deep dive: reading a preclinical literature honestly

Roughly 250 indexed papers exist, and the overwhelming majority are cell and rodent studies. Where humans appear, the work is generally observational: measuring circulating concentrations and correlating them with age, fitness or metabolic state. The 2021 Nature Communications paper is the clearest example of the structure — the human arm measured MOTS-c before and after exercise, finding roughly a 12-fold rise in skeletal muscle against 1.6-fold in circulation, while the interventional work was done in mice. Two inferences the secondary literature routinely makes and the primary literature does not support: that a correlation between low concentrations and poor metabolic health establishes direction, and that a molecule which rises during exercise would reproduce exercise if administered.

Research applications

▸Study of mitochondrial-derived peptides and retrograde signalling
▸AMPK pathway research through non-canonical activation
▸One-carbon and folate-cycle metabolism models
▸Exercise physiology and mitochondrial bioenergetics research
▸Ageing biology and mitochondrial genome expression studies

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the primary degradation route (+16 Da per residue)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check mass spectrometry for +16 and +32 satellites before relying on a batch

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading exercise induction as proof that administration mimics exercise

Fix: The papers report that exercise raises MOTS-c. The reverse inference is not supported and is not claimed.

✗ Treating human observational data as interventional evidence

Fix: Human work measures endogenous concentrations; administration studies were conducted in mice.

✗ Assuming MOTS-c has a cell-surface receptor like humanin

Fix: No receptor is established. Its characterised activity is intracellular.

✗ Storing reconstituted material as though it were as stable as the powder

Fix: Solution-phase material is subject to hydrolysis and oxidation; the lyophilised form is far more stable.

✗ Overlooking WADA status in athlete-adjacent research

Fix: MOTS-c is on the prohibited list; this is relevant to any research context involving competitors.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How much methionine does MOTS-c contain?: Two residues of sixteen — 12.5%, against roughly 2.3% across proteins generally, so about five-fold enriched.
Why is it so methionine-rich?: It is encoded in mitochondrial DNA, whose genetic code reassigns AUA from isoleucine to methionine — a change argued to exist for antioxidant reasons.
What does that mean in practice?: Two oxidation-prone sites rather than one, producing diagnostic +16 and +32 Da satellites alongside the 2,174.6 Da parent mass.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MOTS-c (Mitochondrial Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum